The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myelom
Journal Article
2015-03-20
Permanent link to this Item
Authors
Journal Title
PLoS ONE
Link to Journal
Journal ISSN
Volume Title
Publisher
PLoS One
Publisher
University of Cape Town
Department
Faculty
Series
Abstract
The malignant cell phenotype of Multiple Myeloma (MM) remains unclear with studies proposing
it to be either clonotypic B or proliferating plasma cells. Cancer/testis antigen MAGE
C1 is being extensively studied in MM and it has been suggested that it is involved in the
pathogenesis of the cancer. Therefore, we report on the use of MAGE C1 to determine the
malignant cell phenotype in MM using flow cytometry. Bone marrow aspirate (BM) and peripheral
blood (PB) was collected from twelve MM patients at diagnosis, as well as three
MM disease-free controls. Mononuclear cells were isolated using density-gradient centrifugation,
and stabilized in 80% ethanol, before analysis via flow cytometry using relevant antibodies
against B cell development cell-surface markers and nuclear MAGE C1. MAGE C1
expression was observed consistently in the early stem cells (CD34+) and early pro-B to
pre-B cells (CD34+/−/CD19+), as well as the proliferating plasma cells in both the MM PB
and BM, while no expression was observed in the corresponding control samples. Monoclonality
indicated a common origin of these cell types suggesting that the CD34+/MAGE
C1+ are the primary malignant cell phenotype that sustains the downstream B cell maturation
processes. Furthermore, this malignant cell phenotype was not restricted to the BM but
also found in the circulating PB cells.
Introduction
Description
Reference:
Wienand K, Shires K (2015) The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma. PLoS ONE, 10(3): e0120734. doi:10.1371/journal.pone.0120734